Lumexa Imaging Holdings Reports 5.1% Revenue Growth to $264.2 Million in Q2 2026

Lumexa Imaging Holdings, Inc. reported a total revenue of $264.2 million for the three months ended June 30, 2026, marking a 5.1% increase from $251.4 million in the same period of the previous year. The company's net patient service revenue rose to $194.9 million, up from $189.3 million, driven by a 2.9% increase in consolidated same-center revenues. For the six months ending June 30, 2026, total revenues reached $516.7 million, a 4.1% increase compared to $496.4 million in the prior year. The company achieved a net income of $2.7 million for the second quarter, a significant turnaround from a net loss of $7.2 million in the same quarter of 2025.

Operating expenses for the second quarter increased to $259.7 million from $240.2 million, primarily due to higher costs associated with operations and general administrative expenses. The cost of operations, excluding depreciation and amortization, rose by 6.1% to $225.3 million, reflecting increased volumes and associated staffing costs. General and administrative expenses also saw a notable increase of 30.5%, attributed to higher stock-based compensation and costs related to operating as a public company. Despite these increases, the company reported an operating income of $23.0 million for the quarter, down from $27.7 million in the prior year.

Strategically, Lumexa Imaging has expanded its footprint, operating 192 outpatient imaging centers across 14 states as of June 30, 2026, compared to 184 centers a year earlier. The company has also increased its joint venture partnerships, now managing 88 centers through these arrangements. The growth in centers has contributed to a 2.9% increase in net patient service revenue, with a notable rise in management fee and other revenue, which increased by 80.6% to $8.7 million in the second quarter.

The company’s financial position has improved, with total assets increasing to $1.81 billion as of June 30, 2026, compared to $1.76 billion at the end of 2025. Cash and cash equivalents rose to $69.7 million, up from $58.8 million. Lumexa Imaging's long-term debt remained stable at approximately $820 million, with a significant reduction in interest expenses due to refinancing efforts. The company anticipates continued growth through de novo expansions and joint ventures, while also focusing on enhancing operational efficiencies and managing costs effectively.

Looking ahead, Lumexa Imaging remains optimistic about its growth trajectory, driven by increasing demand for advanced imaging services and a diversified payor mix. The company plans to continue investing in technology and expanding its operational capabilities to enhance service delivery and patient care. However, it acknowledges potential risks, including competition and regulatory challenges, which could impact future performance.